TrialSignal
Clinical trial intelligence report
Therapeutic Efficacy and Feasibility Study of Abbott's BurstDR Spinal Cord Stimulators Technology for Painful Diabetic Neuropathy (PDN)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT07250828-Jul 28, 2026
NCT ID
NCT07250828
Status
ENROLLING_BY_INVITATION
Phase
NA
Sponsor
TriCity Research Center
Executive brief
Investment-Ready Snapshot
Therapeutic Efficacy and Feasibility Study of Abbott's BurstDR Spinal Cord Stimulators Technology for Painful Diabetic Neuropathy (PDN) is a NA clinical asset sponsored by TriCity Research Center in Painful Diabetic Neuropathy (PDN), Diabetic Neuropathy, Neuropathic Pain, Chronic Pain. SEO and diligence focus: BurstDR Spinal Cord Stimulation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07250828
Indication
Painful Diabetic Neuropathy (PDN)
Modality
RNA therapy
Target
BurstDR Spinal Cord Stimulation
Intervention
BurstDR Spinal Cord Stimulation
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.